Episode Details

Back to Episodes
New TYKtwo inhibitor Soficitinib from InnoCare Pharma has been approved by CDE for phase

New TYKtwo inhibitor Soficitinib from InnoCare Pharma has been approved by CDE for phase

Published 7 months, 1 week ago
Description
Smf5Yv7iSAZW7lGwgunC
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us